Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges
Rexinoids are selective ligands for the nuclear receptors known as RXRs. They do not bind to the receptors for all-trans-retinoic acid (RARs). Many new rexinoids have been synthesized and then assayed for their ability to suppress proliferation of cancer cells, to inhibit activation of inflammatory cells of the tumor microenvironment, and to prevent carcinogenesis in animal models relevant to human disease. Here we review the literature on the effects of 4 such rexinoids: bexarotene, LG100268, LG101506, and NRX194204. These rexinoids also have potent synergistic effects when used in combination with other active pharmacological agents, and practical clinical applications would benefit from these actions..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current topics in medicinal chemistry - 17(2017), 6, Seite 721-730 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karen T. Liby [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.2174/1568026616666160617090702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC198981008X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC198981008X | ||
| 003 | DE-627 | ||
| 005 | 20230515132332.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568026616666160617090702 |2 doi | |
| 028 | 5 | 2 | |a PQ20170206 |
| 035 | |a (DE-627)OLC198981008X | ||
| 035 | |a (DE-599)GBVOLC198981008X | ||
| 035 | |a (PRQ)b1752-5efffd41423ed2ba99b7f276ae598e490752078ccae568619fd686f85c0599290 | ||
| 035 | |a (KEY)0446467220170000017000600721rexinoidsforpreventionandtreatmentofcanceropportun | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 0 | |a Karen T. Liby |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Rexinoids are selective ligands for the nuclear receptors known as RXRs. They do not bind to the receptors for all-trans-retinoic acid (RARs). Many new rexinoids have been synthesized and then assayed for their ability to suppress proliferation of cancer cells, to inhibit activation of inflammatory cells of the tumor microenvironment, and to prevent carcinogenesis in animal models relevant to human disease. Here we review the literature on the effects of 4 such rexinoids: bexarotene, LG100268, LG101506, and NRX194204. These rexinoids also have potent synergistic effects when used in combination with other active pharmacological agents, and practical clinical applications would benefit from these actions. | ||
| 700 | 0 | |a Michael B. Sporn |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 6, Seite 721-730 |w (DE-627)338770283 |w (DE-600)2064823-6 |w (DE-576)435515160 |x 1568-0266 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:6 |g pages:721-730 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2174/1568026616666160617090702 |3 Volltext |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=17&issue=6&spage=721 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 6 |h 721-730 | ||